Case Study

How Bristol Myers Squibb overhauled working capital to fund its future

An EY-Parthenon team helped BMS establish a cash leadership office as part of an award-winning Treasury transformation. Learn more in this case study.

Lleading a meeting in a modern office
1

The better the question

Can a pharma fund new R&D to innovate its way past a patent cliff?

A treasury department steps up to help pay for major post-merger integration projects and drug R&D while patching an expected revenue decline.


In late 2019, after completing a US$74 billion acquisition of Celgene Corp., leadership at pharmaceutical giant Bristol Myers Squibb (BMS) faced a major financial agenda, including the funding of an ambitious post-merger integration program and the impending expiration of lucrative pharmaceutical patents.

 

The integration launched a wave of transformation and technology excellence initiatives in all parts of the organization. The sense of urgency was especially acute in the BMS Treasury Department, which had also identified the critical need for improved cash flow to support the company’s new capital allocation strategy. With these aims in mind, and to meet ambitious new free cash flow goals, BMS Treasury kicked off a far-reaching overhaul of technology, process and culture. This would eventually lead to a prestigious “Top Treasury Team” overall award win in 2023 and a highly commended winner in the same category in 2024 for excellence across Treasury, including in cash flow management optimization, from UK-based Treasury Today, the leading publication on corporate treasury matters.

 

The merger, one of the largest ever in the pharmaceutical industry, had made the company the leading maker of oncology and hematology drugs, and executives were determined to make the most of the opportunity by integrating the best parts of the combined organizations to create a fully modernized, future-ready company.

 

They also needed to prepare for the expected significant impact of an imminent patent cliff, the scheduled expiration of valuable pharmaceutical patents. Despite owning an impressive product lineup that includes oncology, immunology, cardiovascular and neuroscience therapies, BMS was facing the sunsetting of patents for some major brands, such as Revlimid, used to treat multiple myeloma, as well as cancer treatment Opdivo and blood clot therapy Eliquis, that would open the door to generic competitors.

 

Because of the new financial pressures, as well as the significant ongoing investments required in pharmaceutical R&D, clinical trials and regulatory compliance, effective cash management is crucial. In pharmaceuticals, where market leadership depends on new drug innovation, the ability to fund R&D effectively can make the difference between winners and losers.

 

With investors watching closely, company leaders are under pressure to offset the expected decline in revenue and strengthen the company’s capability to fund both the integration program and new drug development, requiring investment in skills, technology and R&D. Company leadership recognized the urgent need for a strong balance sheet, supported by an empowered Treasury Department and an enterprise-wide cash culture.

 

“We have significant headwinds from the loss of the exclusivity period,” said BMS SVP and Treasurer Sandra Ramos-Alves. “Cash is critical for supporting our existing business pipeline and future business development and to offset the expected loss of revenue.”

 

Driven by the need to support BMS leadership’s capital allocation strategy and desire to create world-class processes, and with the rising cost of capital adding to the pressure, Ramos-Alves and her Treasury team embarked on their “Treasury Forward” program, a multiyear working capital and technology excellence initiative and strategic centerpiece of the company’s global finance transformation. In 2023, BMS listed support from the EY-Parthenon team to help carry out the program and deliver on its cash flow improvement goals.

Earning the right to grow in the pharmaceutical sector

EY helped Bristol Myers Squibb unlock $500M in working capital, giving the “firepower” to invest. Find out how.


 business boardroom data meeting
2

The better the answer

A new cash culture becomes a driver for change

BMS Treasury increased its focus on optimizing cash flow by establishing a cash leadership office.


BMS engaged the EY-Parthenon Working Capital practice to help implement a cash leadership office (CLO) as the centerpiece of its cash management makeover. The CLO is needed because, as a large organization such as BMS grows, processes that affect cash flow become more complex, decision-making tends to become more decentralized, and it becomes challenging to establish the controls and visibility that are necessary to get different departments working toward the same goal, consistently.

While the CLO is designed to eventually oversee all things cash for the whole enterprise, BMS chose a step-by-step approach, starting with several priority functions: Procurement, Accounts Payable, Commercial, Supply Chain and Treasury. The changes establish disciplined cash flow performance monitoring and governance in order-to-cash, procure-to-pay and inventory processes. The program aims to generate additional free cash flow from operations and ultimately improve total shareholder return.

In terms of technology, the transformation had two major objectives: to streamline Treasury processes with advanced automation and to accelerate capabilities to create bold and innovative solutions through a major upgrade of data and analytics.

By accurately forecasting cash flows and managing liquidity, the CLO supports the organization in navigating the long and often unpredictable timelines associated with bringing new drugs to market. This financial foresight allows the company to make strategic decisions, such as pursuing acquisitions, entering new markets or investing in innovative technologies.

Thus, a critical function of the CLO is to “oversee all things cash” and to embed cash flow incentives and accountability throughout the relevant business functions and processes, explained Gerardo Gonzalez, EY-Parthenon Principal, Ernst & Young LLP, who led the engagement team. “We were able to establish a high level of trust, operating with BMS’s financial priorities in mind, teaming with the Treasury team and interacting with third parties,” he said.

Gonzalez noted that, while goals that benefit cash flow — such as extending payment terms for supplies and services and shortening payment collection terms for delivered products — seem obvious, the decision-making levers that affect cash flow are numerous, embedded in diverse parts of the company, and may be closely guarded by the teams that own them.

Despite setting goals designed to benefit the whole firm, the far-reaching cash flow improvement program quickly ran into an example of the type of organizational complexity — internal resistance — that can disrupt a well-intentioned program, such as when Sales or Procurement functions are used to being able to make concessions about timing of payments to win sales or get better deals. A strong free cash flow policy must be supported by a cash culture throughout affected parts of the organization.

When Treasury and the EY-Parthenon team were able to demonstrate the clear cash flow benefits through a yearlong sample assessment, objections fell away, and the critical culture overhaul went ahead.

“These kinds of changes are difficult for a big organization like BMS because it involves a shift in mindset and culture, but it is what we do on a regular basis,” Gonzalez said. “It’s not just a story of the balance sheet and cash flow. We are a people business — people and cash.”

Despite the progress, Ramos-Alves notes that a culture transformation of this magnitude takes time and continuous effort. “I can’t say we have a culture that fully understands the importance of cash,” she said. “I can say we are on a journey to educate the company cross-functionally about the importance of working capital, of cash flow generation.”


Female doctor leading conference
3

The better the world works

A cash-enabled company is ready for future challenges

The company makes a “quantum leap” in its journey to become a cash-focused organization.


“The CLO and related improvements provide BMS with a cash management engine that it did not have before, with appropriate controls over cash management levers and the ability to sustainably identify cash flow improvement opportunities,” Ramos-Alves said. She noted that the project helped the company make a quantum leap in process improvement and achieve a continuous change in mindset, shifting from a P&L-centric toward a cash-focused organization.

“The project helped us create a framework around working capital. The EY-Parthenon team helped us build it from the ground up,” she said. “It gave us more discipline around what we need to do to tackle some areas and helped us identify what the opportunities were. With these metrics, we can track progress and adjust when things aren’t moving as expected, to get the results we need.”

The CLO is already delivering value, helping optimize hundreds of millions of dollars of free cash flow since its inception and focusing on procure-to-pay as a priority. Ramos-Alves also noted that, based on the results so far, the organization plans to expand the scope of the CLO.

“One of the outstanding characteristics of BMS Treasury is its recognition and relentless focus on optimizing and generating cash flow to support the sourcing of innovative and effective life-saving medicines to patients,” said Gonzalez.

The work continues as BMS has engaged the EY-Parthenon team to help with the next stage of the CLO rollout: integrating global supply chain processes into the program.

Related articles

Investing in innovation: unlocking value in MedTech

An analysis of value creation among MedTech sector companies underscores the pivotal role of investment in R&D as a driver of long-term value creation.

Earning the right to grow: how capital efficiency drives TSR performance

Companies should assess their ROIC before pursuing growth. Read the article to explore strategies for improving capital efficiency and success.

Cash forecasting: Difficult, disappointing and more urgent than ever

Weak cash flow forecasting raises costs and weakens long-term planning. Companies that improve cash flow forecasting have greater resiliency.

    Contact us
    Like what you’ve seen? Get in touch to learn more.